Chryseobacterium indologenes in a woman with acute leukemia in Senegal: a case report

Journal of Medical Case Reports

Aissatou Gaye-Diallo³  Souleymane Mboup³  Coumba Toure-Kane³  Halimatou Diop-Ndiaye³  Awa Ba-Diallo³  Becaye Fall²  Safietou Ngom-Cisse³  Seynabou Fall¹  Makhtar Camara³  Arouna Omar³ 

[1] Service de Médecine Interne, Université Cheikh Anta DIOP, CHU Aristide Le Dantec, Dakar, Senegal;Hôpital Principal de Dakar, 1, Avenue Nelson Mandéla, BP 3006 Dakar, Senegal;Laboratoire de Bactériologie-Virologie, Université Cheikh Anta DIOP, CHU Aristide Le Dantec, BP 7325 Dakar, Senegal

关键词: Resistance;    Metallo-β-lactamase;    Leukemia;    Chryseobacterium indologenes;   

Others  :  821969
DOI  :  10.1186/1752-1947-8-138

 received in 2013-09-24, accepted in 2014-03-19,  发布年份 2014

【 摘 要 】

Introduction

This report documents a rare case of Chryseobacterium indologenes urinary tract infection in Senegal. Chryseobacterium indologenes is an uncommon human pathogen reported in hospital outbreaks in Taiwan and there have been some sporadic cases reported in Europe and in the USA mainly from immune-suppressed patients.

Case presentation

This case report describes a 42-year-old woman of Wolof^a ethnicity who was hospitalized in our Department of Internal Medicine in a Senegalese university teaching hospital, with acute leukemia who died of severe sepsis 10 days following her hospitalization. A strain of Chryseobacterium indologenes isolated from her urine sample was resistant to several beta-lactams including ampicillin (minimum inhibitory concentrations ≥256μg/mL), cefotaxime (minimum inhibitory concentrations 32μg/mL) and imipenem (minimum inhibitory concentrations ≥32μg/mL), whereas it was susceptible to piperacillin (minimum inhibitory concentrations 16μg/mL), cefepime (minimum inhibitory concentrations 4μg/mL), ceftazidime (minimum inhibitory concentrations 4μg/mL), trimethoprim-sulfamethoxazole (minimum inhibitory concentrations ≤0.25μg/mL) and all tested quinolones including nalidixic acid (minimum inhibitory concentrations ≤2μg/mL).

Conclusions

Chryseobacterium indologenes although uncommon, is an important pathogen causing infection in hospitalized patients. The management of this infection needs better identification, drug susceptibility testing and monitoring of immunosuppressed patients with long hospitalizations.

【 授权许可】

   
2014 Omar et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 2.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Douvoyiannis M, Kalyoussef S, Philip G, Mayers MM: Chryseobacterium indologenes bacteremia in an infant. Int J Infect Dis 2010, 14(6):e 531-e 532.
• [2]Hsueh PR, Teng LJ, Yang PC, Ho SW, Hsieh WC, Luh KT: Increasing incidence of nosocomial Chryseobacterium indologenes infections in Taiwan. Eur J Clin Microbiol Infect Dis 1997, 16(8):508-574.
• [3]Calderon G, Garcia E, Rojas P, Garcia E, Rosso M, Losada A: Chryseobacterium indologenes infection in a newborn: a case report. J Med Case Rep 2010, 5:10.
• [4]Lin YT, Jeng YY, Lin ML, Yu KW, Wang FD, Liu CY: Clinical and microbiological characteristics of Chryseobacterium indologenes bacteremia. J Microbiol Immunol Infect 2010, 43:498-505.
• [5]Zeba B, De Luca F, Dubus A, Delmarcelle M, Simpore J, Nacoulma JO, Rossolini GM, Frere JM, Docquier JD: IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso. Antimicrob Agents Chemother 2009, 53:4320-4326.
• [6]Bhuyar G, Jain S, Shah H, Mehta VK: Urinary tract infection by Chryseobacterium indologenes. Indian J Med Microbiol 2012, 30:370-372.
• [7]Acosta-Ochoa MI, Rodrigo-Parra A, Rodríguez-Martín F, Molina-Miguel A: Urinary infection due to Chryseobacterium indologenes. Nefrologia 2013, 19:33(4).
• [8]Samb A, Chiron JP, Denis F, Sow A, Diop Mar I: Flavobacterium meningosepticum meningitis. Clinical and bacteriological study of 2 cases treated in Senegal. Bull Soc Med A 1977, 22(1):84-91.
• [9]Bellais S, Poirel L, Leotard S, Naas T, Nordmann P: Genetic diversity of carbapenem-hydrolyzing metallo-b-lactamases from Chryseobacterium (Flavobacterium) indologenes. Antimicrob Agents Chemother 2000, 44:3028-3034.
• [10]Hsueh PR, Teng LJ, Yang PC, Ho SW, Hsieh WC, Luh KT: Clinical and microbiological characteristics of Flavobacterium indologenes infections associated with indwelling devices. J Clin Microbiol 1908–1913, 1996:34.
• [11]Christakis GB, Perlorentzou SP, Chalkiopoulou I, Athanasiou A, Legakis NJ: Chryseobacterium indologenes non-catheter-related bacteremia in a patient with a solid tumor. J Clin Microbiol 2005, 43(4):2021-2023.
• [12]Chen FL, Wang GC, Teng SO, Ou TY, Yu FL, Lee WS: Clinical and epidemiological features of Chryseobacterium indologenes infections: analysis of 215 cases. J Microbiol Immunol Infect 2013, 46(6):425-432.
• [13]Kirby JT, Sader HS, Walsh TR, Jones RN: Antimicrobial susceptibility and epidemiology of worldwide collection of Chryseobacterium spp. Report from the SENTRY Antimicrobial surveillance Program (1997-2001). J Clin Microbiol 2004, 42:445-448.
• [14]Bernardet JF, Hugo C, Bruun B: The Genera Chryseobacterium and Elizabethkingia. The Prokaryotes, 7. New York: Springer; 2006:638-676.
• [15]Yamaguchi Y, Takashio N, Wachino J, Yamagata Y, Arakawa Y, Matsuda K, Kurosaki H: Structure of metallo-beta-lactamase IND-7 from a Chryseobacterium indologenes clinical isolate at 1.65-A resolution. J Biochem 2010, 147(6):905-915.